David Kerr (oncologist)

Last updated

David James Kerr

CBE, MA MD DSc FRCP (Glas & Lon) FRCGP (Hon) FMedSci
Born1956
Glasgow, Scotland
NationalityBritish
EducationUniversity of Glasgow – MD (1987), BSc-Biochemistry (1977)
Years active1992-present
Known forResearch and Treatment of colorectal cancer; Gene Therapy
Medical career
ProfessionMedical Doctor, researcher
FieldOncology
InstitutionsOxford University
ResearchColorectal Cancer, Gene Therapy
Awards
  • Distinguished Harvard Global Health Catalyst Award (2017)
  • Honorary Fellowship of the Royal College of General Practitioners (2007)
  • European Society for Medical Oncology Award(2006)
  • Commander of the Order of the British Empire (2002)
  • NHS Nye Bevan Award for Innovation (2000)
  • European School of Oncology International Award for outstanding contribution to chemotherapy research (1987)

Professor David James Kerr CBE (born 1956, Glasgow) [1] is a British Cancer Researcher. His primary area of research is treatment and management of colorectal cancer. [2]

Contents

He served as Chief Research Advisor at Sidra Medical and Research Center in Doha, Qatar. [3] [4] David James Kerr is Professor of Cancer Medicine and Former Fellow of Corpus Christi College, Oxford. [5] He was also President-Elect for European Society for Medical Oncology (2009). [6]

David James Kerr’s clinical research into adjuvant therapy of early-stage colorectal cancer has contributed to saving thousands of lives over the past two decades. [7]

Early life and education

Kerr was born in 1956 in Glasgow. He attended Dunard Street Primary School, Maryhill, and Eastwood High Secondary School. Knowing from a relatively early age that he wanted to become a doctor having read A. J. Cronin's The Citadel as a child, he went on to study biochemistry and medicine at Glasgow University, and subsequently became an ontological clinical scientist [8] following specialist and fellowship training within the Department of Medical Oncology at the University of Glasgow under Professor S. Kaye (1984–1992). [1]

Career

Beginning in March 1992, Kerr served as Professor of Clinical Oncology at the University of Birmingham and Director of the Clinical Trials Unit where he and Professor Alan Rickinson built the Institute of Cancer Studies. [9]

In 1994, he was appointed Clinical Director of the Regional Cancer Task Force for the West Midlands. [1] There, he developed a "hub and spoke" Network model for cancer services in the region. The key elements of the plan are:

He undertook the first national audit of cancer waiting times for Sir Kenneth Calman, who was then Chief Medical Officer which was one of the drivers which led to the Government creating a National Cancer Plan. [1] [10]

In 2001, he was appointed Rhodes Professor of Clinical pharmacology and Cancer Therapeutics [11] and Head of the Department of Clinical Pharmacology at the University of Oxford. At the same time, he was also asked by the Secretary of State for Health Alan Milburn to undertake a review of NHS research strategy into cancer. [12] The resultant blueprint for the provision of infrastructure to support clinical cancer research in the UK led to the establishment of the NHS Cancer Research Network (NCRN) [13] and the National Translational Cancer Research Network (NTRAC). Kerr was subsequently appointed the Director of NTRAC. [14]

He subsequently worked with colleagues to build an Institute of Cancer Medicine and Cancer Treatment Center in Oxford.[ citation needed ]

In 2004, Kerr was invited by Scotland’s First Minister to chair the work of a National Framework Advisory Group to consider the future shape of the NHS in Scotland. This Group produced three volumes of work, "Building a Health Service Fit for the Future" (Vol I and II) and a web-based data link showing the Reports from the individual action teams. [15] This has been adopted as the blueprint for Scotland’s NHS over the next 20 years.

In 2009, David Kerr temporarily left Oxford University to serve as the Chief Research Advisor at the Sidra Medical and Research Center. He also became a Member of the Supreme Council of Health in April 2009. Although he has since returned to the UK and is no longer affiliated with Sidra, Kerr has made significant contributions to cancer care and research in Europe. He played a leading role in co-chairing the Anglo-French Scientific committee for the centenary of the Entente-Cordiale in 2004, focusing on cancer research as the joint theme of the Queen and President Chirac. Additionally, Kerr successfully established the first network of top cancer centers in India, transforming it into a globally recognized trials network and providing training for numerous young Indian oncologists.[ citation needed ]

He has brought worldwide attention to the looming epidemic of cancer which is a risk of claiming the lives of more than a million Africans every year. [16] He organized the first ever African Cancer Reform convention in London (2007). [17] This was attended by 27 African Health ministries, led to the London Declaration calling for immediate action to develop cancer control plans for these nations. [18] Subsequently Kerr was asked by African ministers to lead a new organization, AfrOx to aid national cancer planning in Africa. AfrOx has already received international support (WHO, IAEA) and is seen as a beacon to establish cancer care in Africa. He has completed a National Cancer Plan for Ghana, has been invited by the governments of Rwanda, Nigeria and Sierra Leone to lead their cancer plan activities, has initiated a mass vaccination program for cervical cancer, the commonest cancer affecting African women, and is coordinating the International Oncology Association's engagement in this field.[ citation needed ]

Kerr spoke at a New Frontiers in Science Diplomacy event [19] and blogged on the Guardian [20] about it.

Published works

Kerr has published over 350 papers in peer reviewed journals. His primary areas of research are colorectal cancer and gene therapy. He has been awarded several patents which have led to spin out biotech companies – Cobra Therapeutics, [21] Oxford Cancer Biomarkers, [22] and Celleron Therapeutics. [23]

He sits on a number of general editorial boards including Nature Reviews Clinical Oncology journal.

Awards and honours

Related Research Articles

<span class="mw-page-title-main">Medical Research Council (United Kingdom)</span> National medical research agency

The Medical Research Council (MRC) is responsible for co-coordinating and funding medical research in the United Kingdom. It is part of United Kingdom Research and Innovation (UKRI), which came into operation 1 April 2018, and brings together the UK's seven research councils, Innovate UK and Research England. UK Research and Innovation is answerable to, although politically independent from, the Department for Business, Energy and Industrial Strategy.

<span class="mw-page-title-main">Beatson West of Scotland Cancer Centre</span> Specialised cancer care centre in Glasgow, Scotland

The Beatson West of Scotland Cancer Centre is a specialised cancer care centre in Glasgow, Scotland. Until recently it had facilities in Gartnavel General Hospital, the Western Infirmary and Glasgow Royal Infirmary. As part of the NHS Greater Glasgow and Clyde Acute Services Review, the centre is being centralised within new facilities at the Gartnavel General Hospital site.

<span class="mw-page-title-main">Gordon McVie</span> British oncologist and cancer researcher (1945–2021)

John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.

Karol Sikora is a British physician specialising in oncology, who has been described as a leading world authority on cancer. He was a founder and medical director of Rutherford Health, a company that provided proton therapy services, and is Director of Medical Oncology at the Bahamas Cancer Centre.

Allied Academies is a reportedly fraudulent corporation chartered under the laws of North Carolina. Its postal address is in London, United Kingdom. It presents itself as an association of scholars, with supporting and encouraging research and the sharing and exchange of knowledge as its stated aims. The organization consists of 30 affiliate academies, which provide awards to academics and publish academic journals both online and in hard copy for members. Since 2015 the organization has been listed on Jeffrey Beall's list of "potential, possible, or probable predatory scholarly open-access publishers". It is in a partnership with OMICS Publishing Group which uses its website and logo. In 2018, OMICS owner Srinubabu Gedela declared that he had informed the Nevada court that Allied Academies was a subsidiary of OMICS International. During a conference in 2018, they falsely listed a prominent chemist among its organizing committee who had not agreed to this and was not affiliated with Allied Academies.

Professor Dame Janet Elizabeth Husband is Emeritus Professor of Radiology at the Institute of Cancer Research. She had a career in diagnostic radiology that spanned nearly 40 years, using scanning technology to diagnose, stage, and follow-up cancer. She continues to support medicine and research as a board member and advisor for various organisations.

<span class="mw-page-title-main">Hani Gabra</span>

Hani Gabra PhD FRCPE FRCP is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London.

Janusz Jankowski is a doctor, educationalist and scientist of Scottish Polish origin He is an expert in Social and Healthcare Policy, Academic Management and Global Research and Education Networks He was formerly in previous senior management roles including Deputy Vice Chancellor of Research and Innovation, Pro Vice Chancellor Research, Vice Dean Research and the Sir James Black Professorship.

<span class="mw-page-title-main">Michael Adrian Richards</span> Oncologist and cancer researcher

Professor Sir Michael Adrian Richards, CBE, MD, DSc (Hon), FRCP is a British oncologist. From 1999 to 2013 he was the National Cancer Director in the UK Government's Department of Health. He was appointed to be the Chief Inspector of Hospitals in the Care Quality Commission on 31 May 2013. and was said by the Health Service Journal to be the third most powerful person in the English NHS in December 2013.

<span class="mw-page-title-main">Edinburgh Cancer Research Centre</span> Medical facility in City of Edinburgh, Scotland, UK

The Edinburgh Cancer Research Centre (ECRC), also known as the Cancer Research UK Edinburgh Centre and the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.

Leonard W. Seymour is a Professor of Gene Therapy at the University of Oxford's oncology department. As a cancer-oriented translational researcher, he investigates technologies utilised to enhance targeted therapy's delivery and develops related biological therapeutics under the support of Cancer Research UK.

Professor D. Gareth R. EvansFLSW is a British medical geneticist.

<span class="mw-page-title-main">Charles Swanton</span>

(Robert) Charles Swanton is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.

Luis Alberto Diaz, Jr. is the Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine.

Daniel Hochhauser is a British oncologist, and Kathleen Ferrier Professor of Medical Oncology at University College London.

<span class="mw-page-title-main">Andrew Biankin</span>

Andrew Victor Biankin is a Scotland-based Australian clinician-scientist, best known for his work on enabling precision oncology in learning healthcare systems by integrating discovery, preclinical and clinical development to accelerate novel therapeutic strategies, and developing standardised pan-cancer assays for use by healthcare systems and researchers worldwide.

The University of Glasgow's Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer.

<span class="mw-page-title-main">Edith Mitchell</span> American oncologist and USAF officer

Edith Peterson Mitchell is a retired Brigadier general of the United States Air Force and an oncologist. She is clinical professor of medicine and medical oncology at Thomas Jefferson University. In 2015, she became the president of the National Medical Association.

Scott A. Waldman is an MD and biomedical scientist at Sidney Kimmel Medical College of Thomas Jefferson University, where he is the Samuel M.V. Hamilton Professor of Medicine, and also tenured professor and chair of the Department of Pharmacology & Experimental Therapeutics. He is author of a pharmacology textbook, and former chief editor of Clinical Pharmacology & Therapeutics. He is known for his work in atrial natriuretic factor intracellular signaling through guanylate cyclase (GC), and the relation of Guanylyl cyclase C (GC-C) to the pathogenesis of colorectal cancer. Also for his hypotheses concerning the roles of intestinal paracrine hormones in satiety, obesity and cancer risk. Waldman also holds a concurrent position as adjunct professor at the University of Delaware, School of Health Sciences.

Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.

References

  1. 1 2 3 4 "David Kerr new Editor-in-Chief of Annals of Oncology | Annals of Oncology | Oxford Academic" (PDF). Annonc.oxfordjournals.org. 1 September 1999. Retrieved 25 December 2018.[ dead link ]
  2. ↑ Sidra Medicine. "Sidra Medicine | Hospital in Qatar" (PDF). Sidra.org. Retrieved 25 December 2018.[ permanent dead link ]
  3. ↑ "New frontiers in science diplomacy" (PDF). The Royal Society Science Policy Centre. January 2010. p. 32. Retrieved 24 May 2023.
  4. ↑ Kermani, Faraz (4 March 2010). "How to run clinical trials in the Middle East - Qatar". Scrip World Pharmaceutical News .
  5. ↑ Sidra Medicine. "Sidra Medicine | Hospital in Qatar". Sidra.org. Retrieved 25 December 2018.[ permanent dead link ]
  6. ↑ "European Society for Medical Oncology Committees | Annals of Oncology | Oxford Academic" (PDF). Annonc.oxfordjournals.org. 1 September 2008. Retrieved 25 December 2018.[ dead link ]
  7. ↑ Lancet, 370(9604):2020-9. 2007; The Lancet, 355, 1588–96 (2000)
  8. ↑ "Cancer hit squad". Archived from the original on 5 December 2008. Retrieved 3 September 2009.
  9. ↑ The Committee Office, House of Commons. "House of Commons - Science and Technology - Appendices to the Minutes of Evidence". Publications.parliament.uk. Retrieved 25 December 2018.
  10. ↑ British Medical Journal 320, 838–839.
  11. ↑ "Oxford University Gazette, 11 January 2001: Notices". Archived from the original on 2 September 2007. Retrieved 3 September 2009.
  12. ↑ The Committee Office, House of Commons. "House of Commons - Science and Technology - Minutes of Evidence". Publications.parliament.uk. Retrieved 25 December 2018.
  13. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 16 October 2009. Retrieved 3 September 2009.{{cite web}}: CS1 maint: archived copy as title (link)
  14. ↑ The Committee Office, House of Commons. "House of Commons - Science and Technology - Appendices to the Minutes of Evidence". Publications.parliament.uk. Retrieved 25 December 2018.
  15. ↑ framework
  16. ↑ "Africa's looming cancer epidemic". BBC News. 12 June 2008. Retrieved 1 May 2010.
  17. ↑ "Untitled Document". Archived from the original on 18 April 2009. Retrieved 3 September 2009.
  18. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 1 September 2009. Retrieved 3 September 2009.{{cite web}}: CS1 maint: archived copy as title (link)
  19. ↑ "Sorry". Royal Society. Retrieved 25 December 2018.
  20. ↑ Kerr, David (22 June 2009). "Science can bridge national divides". The Guardian. London. Retrieved 1 May 2010.
  21. ↑ "Celleron Therapeutics - Management". Archived from the original on 8 July 2011. Retrieved 3 September 2009.
  22. ↑ "Oxford Cancer Biomarkers – Pioneering precision medicine". Oxfordbio.com. Retrieved 25 December 2018.
  23. ↑ "Celleron Therapeutics". Celleron Therapeutics. Retrieved 25 December 2018.
  24. 1 2 3 http://www.worldgicancer.com/WCGI/WGIC2009/About%20ESMO.pdf%5B%5D
  25. 1 2 "Professor David Kerr – Department of Clinical Pharmacology". University of Oxford. 19 June 2008. Archived from the original on 23 April 2010. Retrieved 3 September 2009.
  26. ↑ "'NHS Oscars' Awarded To NHS Modernisers". 5 July 2005.
  27. ↑ "New Year's Honours List — United Kingdom". The London Gazette . 31 December 2001. p. 8. ISSN   0374-3721 . Retrieved 24 May 2023.
  28. ↑ "Awards and Fellowships 2007" (PDF). Royal College of General Practitioners.[ permanent dead link ]
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.